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Abstract
Background: Hyperlipidemia and hypertension are well-established risk factors for recurrent cardiovascular
events among patients with ischemic heart disease (IHD). Despite national recommendations, concordance with
guidelines for LDL cholesterol and blood pressure remains inadequate. The objectives of this study were to 1)
determine concordance rates with LDL cholesterol and BP recommendations; and 2) identify patient factors,
processes and structures of care associated with guideline concordance among VA IHD patients.
Methods:  This was a cross sectional study of veterans with IHD from 8 VA hospitals. Outcomes were
concordance with LDL guideline recommendations (LDL<100 mg/dl), and BP recommendations (<140/90 mm
Hg). Cumulative logit and hierarchical logistic regression analyses were performed to identify patient factors,
processes, and structures of care independently associated with guideline concordance.
Results: Of 14,114 veterans with IHD, 55.7% had hypertension, 71.5% had hyperlipidemia, and 41.6% had both
conditions. Guideline concordance for LDL and BP were 38.9% and 53.4%, respectively. However, only 21.9% of
the patients achieved both LDL <100 mg/dl and BP <140/90 mm Hg. In multivariable analyses, patient factors
including older age and the presence of vascular disease were associated with worse guideline concordance. In
contrast, diabetes was associated with better guideline concordance. Several process of care variables, including
higher number of outpatient visits, higher number of prescribed medications, and a recent cardiac hospitalization
were associated with better guideline concordance. Among structures of care, having on-site cardiology was
associated with a trend towards better guideline concordance.
Conclusion:  Guideline concordance with secondary prevention measures among IHD patients remains
suboptimal. It is hoped that the findings of this study can serve as an impetus for quality improvement efforts to
improve upon secondary prevention measures and reduce the morbidity and mortality of patients with known
IHD.
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Background
Hyperlipidemia and hypertension are prevalent and often
co-existing conditions among patients with ischemic
heart disease (IHD) [1]. Prior studies have found signifi-
cant gaps in the achievement of nationally recommended
low-density lipoprotein (LDL) cholesterol and blood
pressure (BP) levels [2-5]. A basic principle of prevention
is that intensity of risk reduction therapy should be
adjusted to a person's overall risk [6]. Within 6 years of an
initial event, up to one-third of patients will have a recur-
rent myocardial infarction, and almost 50% of women
will be disabled with congestive heart failure [7]. In addi-
tion, the risk of a future IHD event, according to the Fram-
ingham risk estimates, is based on multiple factors
including blood pressure level, cholesterol level, smoking
status, and age [8]. Therefore, given the high absolute risk
of recurrent cardiovascular events among IHD patients,
studies addressing secondary prevention care should
encompass multiple risk factors (e.g., hyperlipidemia and
hypertension). However, prior studies assessing guideline
concordance with secondary prevention measures have
focused mainly on either hyperlipidemia or hypertension
alone within any one study.
To improve secondary prevention care, factors associated
with guideline concordance or non-concordance need to
be further elucidated. One approach is to use the proc-
esses, structures and outcomes of care model [9] devel-
oped by Donabedian. He linked the three elements by
stating that "good structure increases the likelihood of
good process, and good process increases the likelihood
of a good outcome." This model can be used to identify
specific factors that are associated with guideline non-con-
cordance and these factors can serve as focus areas for
quality improvement interventions. Accordingly, our
objectives were to assess guideline concordance for sec-
ondary prevention care based on LDL cholesterol and
blood pressure control and to identify specific patient,




All active patients with IHD enrolled in primary care clin-
ics in any one of eight Pacific Northwest Veterans Affairs
(VA) hospital facilities in Veterans Integrated Service Net-
work (VISN) 20 were included in the study. Patients with
IHD were identified by any one or more of the following
International Classification of Diseases-9th revision
(ICD-9) diagnosis codes in the 24 months before the
index date (October 1, 2000), based on a previously vali-
dated algorithm: 410.x, 411.x, 412, or 414.x [2,10]. We
searched for these diagnosis codes in the active problem
list file of the VA computerized medical record, the outpa-
tient care (OPC) file, and the patient treatment file (PTF).
The OPC file contains data on all outpatient visits,
whereas the PTF file contains data on all inpatient
encounters. These files are part of the Consumer Health
Information & Performance Sets (CHIPS) Data Ware-
house [11], which is a relational database mirroring the
clinical information system residing at each VA Medical
Center and outpatient facility in VISN 20.
Active patients were defined as being alive on October 1,
2000 (index date), and having at least one primary care
clinic visit documented in the OPC file per year in each of
the two previous years. A primary care visit was defined
using the OPC file as any visit to one or more of the fol-
lowing clinics: General Internal Medicine, Women's
Clinic, Primary Care/Medicine, or Geriatrics.
Independent variables
Clinical characteristics were defined by ICD-9 codes
within either the OPC and/or PTF files within the 15
months before the index date: percutaneous coronary
intervention (PCI), coronary artery bypass graft (CABG)
surgery, diabetes, hypertension, hyperlipidemia, chronic
obstructive pulmonary disease, peripheral vascular dis-
ease, cerebrovascular disease, myocardial infarction, con-
gestive heart failure, malignancy, smoking status, and
renal disease. The distance to medical center was calcu-
lated using the longitude and latitude coordinates of a
patient's home address, based on their zip code and the
longitude and latitude coordinates [12] of the medical
center based on the medical center zip code.
Recent cardiac hospitalization for an acute coronary syn-
drome (ACS) or coronary revascularization procedure(s)
(i.e., PCI and/or CABG) were defined as occurring within
the 15 months before the index date. Hospital admission
for ACS was defined by a primary discharge diagnosis
based on ICD-9 codes 410.x or 411.x in the PTF file. The
number of outpatient clinic visits was aggregated over the
15 months before the index date.
Patients were defined as having a current medication pre-
scription for the following classes of medications if they
had a prescription written or renewed within the last 15
months before the index date: aspirin, beta-blockers, angi-
otensin-converting enzyme (ACE) inhibitors or angi-
otensin receptor blockers, calcium channel blockers,
diuretics, and 3-hydroxy-3-methylglutaryl coenzyme-A
reductase inhibitors (statins). Patients frequently obtain
aspirin over-the-counter rather than at VA pharmacies
because of the lower cost and therefore rates of aspirin use
are likely to be higher compared to the pharmacy prescrip-
tion data. The total number of medications was based on
the sum of all active prescriptions for the patient within 6
months from the beginning of the study period.BMC Cardiovascular Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2261/6/6
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Facility level data were obtained from the VISN Support
Service Center website [13], a health care information and
technical support organization serving the needs of the
networks. Data on volume of primary care patients and
visits were obtained for each of the eight facilities
included in the analysis. Clinic volume was defined by the
number of visits to the primary care clinics at each of the
8 hospitals in the study for the month of December 2000.
The number of visits ranged from 3,821 to 18,613. On-
site cardiologist was defined as the presence of a cardiolo-
gist based at a hospital. Five of the eight hospitals in the
study had an on-site cardiologist.
Dependent variables
The primary outcomes of interest were achievement of: 1)
LDL <100 mg/dl; and 2) BP <140/90 mm Hg [6,14], con-
sistent with national guidelines as treatment targets for
patients with underlying IHD. The combined outcome
was defined as achievement of both LDL <100 mg/dl and
BP <140/90 mm Hg. Any lipid level measured within 15
months before the index date was included, and the most
current LDL level was used in the analyses. A LDL meas-
urement was available for 83.4% of the patients. The LDL
outcome variable was categorized into 3-levels of guide-
line concordance with each lower category indicating bet-
ter concordance compared to a higher category: 0) LDL
measurement and LDL <100 mg/dl, 1) LDL measurement,
but LDL≥100 mg/dl, and 2) no LDL measurement.
The majority of patients (94.9%) had at least one BP
measurement within the six months prior to the index
date. Among patients with two or more BP measurements,
the BP readings were averaged to get a better reflection of
the true blood pressure. The BP outcome variable was also
categorized into 3-levels of guideline concordance with
each lower category indicating better concordance com-
pared to a higher category: 0) SBP<140 and DBP<90 mm
Hg; 1) SBP≥140 or DBP≥90 mm Hg, and 2) no BP meas-
urement.
Statistical analysis
The main objectives of our study were to identify specific
patient, processes of care and structures of care factors
associated with guideline concordance. We hypothesized
a priori that the following patient factors would be associ-
ated with worse guideline concordance: older age, longer
distance from home to medical center, diabetes and vas-
cular disease (i.e. peripheral and/or cerebrovascular dis-
ease). For processes of care, we hypothesized a priori that
the following factors would be associated with worse
guideline concordance: higher total number of medica-
tions, lower number of outpatient visits and recent hospi-
talization for a cardiac event. Hospitalizations and cardiac
procedures were categorized as process variables because
the primary outcomes of interest were achievement of
LDL and BP goals. Finally, for structures of care, we
hypothesized a priori that the following factors would be
associated with worse guideline concordance: lower pri-
mary care clinic volume and facility does not have an on-
site cardiologist.
Table 2: Processes of care for the study population
Processes of care N (%)
Recent hospitalization
Acute coronary syndrome hospitalization 534 (3.8%)
Percutaneous coronary intervention 213 (1.5%)
Coronary artery bypass graft surgery 284 (2.0%)
Outpatient visit history
Total number of visits, mean (STD) 8.7 (7.0)
Total number of primary care visits, mean (STD) 7.3 (6.2)
Total number of specialty care visits, mean (STD) 1.6 (3.3)
Primary care clinic visit 13,425 (95.1%)
Cardiology clinic visit 3,862 (27.4%)
Medication history
Total number of medications, mean (STD) 11.2 (6.0)
Aspirin prescription 7,051 (50.0%)
ACEi or ARB prescription 8,024 (56.8%)
β-blocker prescription 8,209 (58.2%)
CCB prescription 5,238 (37.1%)
Diuretic prescription 6,650 (47.1%)
Any lipid-lowering agent prescription 9,020 (63.9%)
Statin prescription 8,060 (57.1%)
Table 1: Baseline characteristics of the study population 
(N = 14,114)
Patient characteristics N (%)
Age, mean years (STD)*# 68.1 (10.5)
Male gender 13,802 (97.8%)
White race 12,040 (85.3%)
Married* 8,246 (58.4%)
Distance from home to medical center, mean miles 
(STD)
71.6 (203)
Prior myocardial infarction* 1,557 (11.0%)
Prior percutaneous coronary intervention*# 1,278 (9.0%)
Prior coronary artery bypass graft surgery*# 2,971 (21.0%)




Obese (BMI>30 kg/m2)# 6,048 (42.8%)
Smoker 2,909 (20.6%)
Chronic obstructive pulmonary disease# 4,201 (29.8%)
Cerebrovascular disease# 1,542 (10.9%)
Peripheral vascular disease# 1,613 (11.4%)
Renal disease 845 (6.0%)
Malignancy# 1,711 (12.1%)
*Significantly associated with LDL guideline concordance
#Significantly associated with BP guideline concordanceBMC Cardiovascular Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2261/6/6
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In our multivariable regression analyses, the cumulative
logit model was used because there were 3 categories in
both outcome variables. This model reports the odds
ratio, which estimates the probability that each subject is
in a lower (i.e., better concordance) category compared to
a higher (i.e., worse concordance) category of guideline
concordance.
Since we were interested in the association between spe-
cific factors and guideline concordance, our multivariable
risks models were constructed specifically to test the inde-
pendent association between each of the hypothesis vari-
ables and guideline concordance, adjusting for baseline
patient characteristics. To test the association between
specific patient factors and guideline concordance, a base-
line patient level risk model was constructed consisting of
patient demographic factors, cardiac and non-cardiac co-
morbidities as listed in Table 1. Backward selection was
performed (p < 0.05 to stay in model) to identify a parsi-
monious group of patient level factors associated with
guideline concordance for risk adjustment. Then, each
candidate independent variable of interest for hypothesis
testing was individually entered into this baseline risk
model to determine its association with the outcome of
interest. Odds ratio and 95% confidence intervals are
reported for each of the significant variables in the risk
models.
Risk models for the process of care analysis were built in a
similar fashion as described for patient factors. A baseline
risk model consisting of all significant patient-level factors
identified in the prior analyses and the primary facility
where a patient received care was constructed for risk
adjustment. Then each of the process of care hypothesis
variables was individually entered into the risk model to
test the independent association between the variable and
the outcome of interest.
The structures of care analyses were performed at the facil-
ity level using a hierarchical logistic regression model with
a random facility effect that accounts for the clustering of
patients by facilities. Models were estimated using maxi-
mum likelihood with the SAS procedure NLMIXED [15].
Multivariable hierarchical regression models were built to
test the hypothesis of interest, accounting for clustering of
patients within sites.
Based on the multivariable analyses, we identified several
patient factors and processes of care variables that were
associated with guideline concordance. To enhance clini-
cal interpretability of the results, we evaluated the associ-
ation between the number of factors present versus
guideline concordance, using the chi-square test to assess
for a trend in this association.
All analyses were performed using SAS (Version 8.02, SAS
Institute) [14]. The study was approved by the Colorado
Multiple Institutional Review Board.
Results
Overall, 14,114 patients were identified as having IHD
(Table 1). The majority of the IHD patients were male and
the mean age was 68.1 ± 10.5 (mean ± STD). These
patients had a number of co-morbid conditions with
71.5% having a diagnosis of hypertension, 55.7% having
a diagnosis of hyperlipidemia, and 41.6% having both of
these conditions. They had frequent outpatient visits
(mean 8.7 ± 7.0 visits) over a 15-month period and were
prescribed multiple medications (mean of 11.2 ± 6.0
medications) (Table 2).
Guideline concordance for LDL cholesterol and BP were
suboptimal (Figure 1). Only 38.9% of the patients had a
LDL<100 mg/dl and 16.6% of the patients did not have a
current LDL measurement. For BP control, 53.4% of the
patients had a BP<140/90 mm Hg and 5.1% of the
patients did not have a current BP measurement. When
guideline concordance was based on both achievement of
LDL<100 mg/dl and BP<140/90 mm Hg, only 21.9% of
the patients met these targets. A significant proportion of
patients, 29.5%, met neither LDL nor BP goals.
The multivariable findings are presented in Table 3. For
the LDL outcome, older age (OR 0.94, per 10 years; 95%
CI 0.91–0.97; p < 0.01) was associated with worse guide-
line concordance. In contrast, diabetes (OR 1.44; 95% CI
Guideline concordance for LDL cholesterol and blood pres- sure Figure 1
Guideline concordance for LDL cholesterol and blood pres-
sure. * Patients were grouped into exclusive categories for 
"LDL and BP at goal' and 'LDL or BP at goal'. Therefore, 
patients at both LDL and BP goal were not placed in the 
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1.35–1.54; p < 0.01), total number of prescribed medica-
tions (OR 1.01, per 1 medication; 95% 1.00–1.01; p <
0.01), total number of outpatient visits (OR 1.02, per 1
visit; 95% CI 1.01–1.02; p < 0.01), and recent cardiac hos-
pitalization (OR 1.28; 95% CI 1.11–1.49; p < 0.01) were
associated with better guideline concordance.
For the BP outcome, older age (OR 0.86, per 10 years 95%
CI 0.83–0.89; p < 0.01) and the presence of vascular dis-
ease, cerebrovascular and/or peripheral vascular disease
(OR 0.91; 95% CI 0.84–0.99; p = 0.03) were both associ-
ated with worse BP control. In contrast, total number of
medications (OR 1.01, per 1 medication; 95% CI 1.00–
1.01; p = 0.03), total number of outpatient visits (OR
1.02, per 1 visit; 95% CI 1.01–1.02; p < 0.01), and recent
cardiac hospitalization (OR 1.34; 95% CI 1.14–1.57; p <
0.01) were associated with better BP concordance.
For the structures of care analysis, there was a trend for an
association between on-site cardiology and better LDL
(OR 1.14; 95% CI 1.00–1.30; p = 0.04) and BP (OR 1.10;
95% CI 0.99–1.12; p = 0.10) guideline concordance. In
contrast, higher clinic volume was associated with worse
BP concordance (OR 0.82; 95% CI 0.68–0.99; p < 0.01).
Finally, there was a graded inverse relationship between
the number of factors present (i.e., age≥65, presence of
vascular disease, lack of diabetes, and lack of recent car-
diac hospitalization) and guideline concordance. LDL
concordance ranged from 55% for those without any of
the identified factors to 36% for those with all 4 factors
(Figure 2). Similarly, BP concordance ranged from 72%
for those without any factors to 50% for those with all 4
factors. Achievement of both LDL cholesterol and BP
goals (data not shown) ranged from 47% when no factors
were present to 31% when all 4 factors were present (p <
0.01 for trend for all).
Discussion
The objectives of this study were to assess guideline con-
cordance for secondary prevention care based on LDL
cholesterol and blood pressure control and to identify
specific patient, processes of care and structures of care
factors associated with guideline concordance. We found
that achievement of guideline recommendations for LDL
(<100 mg/dl), and BP (<140/90 mm Hg) were 38.9%,
and 53.4%, respectively. When concordance was assessed
more globally, based on both LDL and BP control, less
than one-quarter of patients were at target.
Several factors were associated with guideline concord-
ance based on our multivariable analyses. Patient factors
including older age and vascular disease were associated
with worse guideline concordance, while diabetes was
associated with better guideline concordance. Processes of
care measures, including higher total number of medica-
tions, higher total number of outpatient visits, and recent
cardiac hospitalization were associated with better guide-
line concordance. Finally, clinic volume and on-site cardi-
ology were associated with guideline concordance;
however, given the small number of facilities (n = 8), and
the fact that many of the structural characteristics were
highly correlated with each other, definitive conclusions
cannot be made regarding the structures of care variables.
Table 3: Multivariable analyses for the association between the hypothesis variables and guideline concordance*#
Hypothesis variables LDL concordance (95% CI; p-value) BP concordance (95% CI; p-value)
Patient factors
Age (per 10 year increment) 0.94 (0.91–0.97; p < 0.01) 0.86 (0.83–0.89; p < 0.01)
Distance to medical center (per 25 mile 
increment)
0.99 (0.99–1.00; p = 0.19) 0.99 (0.99–1.00; p = 0.30)
Diabetes 1.44 (1.35–1.54; p < 0.01) 1.01 (0.94–1.08; p = 0.89)
Vascular disease& 0.99 (0.91–1.07; p = 0.76) 0.91 (0.84–0.99; p = 0.03)
Processes of care
Total medications (per 1 medication 
increment)
1.01 (1.00–1.01; p < 0.01) 1.01 (1.00–1.01; p = 0.03)
Total Visits (per 1 visit increment) 1.02 (1.01–1.02; p < 0.01) 1.02 (1.01–1.02; p < 0.01)
Recent cardiac hospitalization 1.28 (1.11–1.49; p < 0.01) 1.34 (1.14–1.57; p < 0.01)
Structures of care
Clinic volume 1.01 (1.00–1.02; p = 0.76) 0.82 (0.68–0.99; p < 0.01)
On-site cardiologist 1.14 (1.00–1.30; p = 0.04) 1.10 (0.99–1.22; p = 0.10)
*The cumulative logit model estimates the probability that each subject is in a lower (i.e., better) category compared to a higher (i.e., worse) 
category of guideline concordance. The reported odds ratio is the probability of being in a lower category (i.e., better concordance) compared to a 
higher category (i.e., worse concordance). The outcome categories for LDL were the following: 0) LDL measurement and LDL <100 mg/dl, 1) LDL 
measurement, but LDL≥100 mg/dl, and 2) no LDL measurement. The outcome categories for BP were the following: 0) SBP<140 and DBP<90 mm 
Hg; 1) SBP≥140 or DBP≥90 mm Hg, and 2) no BP measurement.
#Candidate covariates included all Table 1 and 2 variables.
&Presence of cerebrovascular and/or peripheral vascular diseaseBMC Cardiovascular Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2261/6/6
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In contrast to prior studies, we focused exclusively on
patients with known IHD and assessed guideline concord-
ance for both hyperlipidemia and hypertension. Prior
studies evaluating concordance with guideline recom-
mendations for secondary prevention measures have
mainly focused on either LDL cholesterol or blood pres-
sure in any one study and not both of these co-morbidi-
ties together. In previous studies, rates of achieving LDL
<100 mg/dl among those with a LDL measurement have
ranged from 30–50% [2,3,16] with significant variability
depending on the patient population and study setting.
For hypertension control, studies have not exclusively
focused on patients with known coronary disease, who
comprised only up to 30% of the patients in any one of
the studies. In these studies, blood pressure was control-
led in only approximately 40% [4,5,17] of the popula-
tion. Pedrinelli, et al. recently evaluated global risk in a
cohort of hypertensive patients and noted low rates of
achievement of both LDL cholesterol and BP targets.
Among the highest risk patients, those defined as having
a 10 year risk for a IHD event >20% or those with known
IHD, BP averaged 170/110 mm Hg and the mean LDL
cholesterol was 148 mg/dl [18]. Together, these studies
highlight a need to apply a global approach to risk factor
modification, especially among those with known IHD,
who are at high risk for recurrent cardiovascular events.
Rates of guideline concordance for LDL cholesterol and
BP noted in the current study are similar to, if not better
than those reported in the literature, and are consistent
with prior studies supporting the quality of VA care com-
pared to non-VA settings. For example, Jha, et al. com-
pared VA to Medicare fee-for-service for multiple
outpatient chronic conditions and found that the VA out-
performed Medicare fee-for-service on 12 of 13 indicators
in the year 2000 [19]. For lipid screening among diabetics,
the rate was significantly higher among veterans com-
pared to the Medicare fee-for-service patients (89% vs.
60%). Asch, et al. also noted better performance on many
of the quality indicators for outpatient care among VA
patients compared to a national community sample [20].
The adjusted rates of adherence to hyperlipidemia and
hypertension indicators were 64% and 78%, respectively
for VA patients compared to 53% and 65%, respectively
for the community sample patients. These studies, along
with the findings of the current study, thereby support a
higher level of quality of care among veterans in the out-
patient setting, although significant room for improve-
ment remains.
Overall, achievement of secondary prevention measures,
both within and outside of the VA, remains suboptimal.
Among patients above LDL goal, 38% of the patients were
not prescribed any lipid-lowering medications and
among patients above BP targets, 9% of the patients were
not prescribed any antihypertensive medications in our
study. Conditions such as hyperlipidemia and hyperten-
sion are often asymptomatic and less likely to be empha-
sized during outpatient visits that are frequently centered
on acute problems and conditions. In addition to intensi-
fying medical therapy (i.e., starting new medications or
increasing dosages of existing medications), current proc-
esses of care can be modified to improve control of these
measures. For example, computerized reminders directed
at care providers [21,22] as a component of a multi-fac-
eted intervention can be implemented to identify high-
risk patients (e.g., high-risk based on the factors identified
in this study) requiring aggressive treatment. In addition,
outpatient visits, following the Chronic Care Model para-
digm [23], can be planned to specifically focus on second-
ary prevention measures. These planned visits would
allow care providers the necessary time to titrate therapy
for these conditions. Similarly, disease management pro-
grams targeting secondary prevention measures can be
established to complement usual care. Initial studies of
disease management programs for various cardiovascular
conditions [24] have been promising. Prospective rigor-
ously designed studies are needed to determine whether
changes to current care processes can improve LDL choles-
terol and BP control among IHD patients.
Furthermore, interventions directly targeting patients can
be implemented to improve self-management and
increase patient adherence to recommended therapies.
Telehealth technologies, such as interactive voice
response, the Internet or Health Buddies [25,26] (i.e., an
in-home technology device) can be incorporated into rou-
tine patient follow-up. These technologies can increase
patient contact with the healthcare system, without add-
Guideline concordance based on the number of factors  present Figure 2
Guideline concordance based on the number of factors 
present. Factors: age≥65, presence of vascular disease, lack 
of diabetes, lack of recent cardiac hospitalization. p < 0.01 for 
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ing to clinic visits. Interactive voice response (IVR) tech-
nology has been shown to increase patient adherence with
medications, as well as improve some intermediate out-
comes such as blood pressure and glycemic control [25].
These telehealth technologies should be examined pro-
spectively in clinical trials to determine if the addition of
these technologies to usual care improves guideline con-
cordance.
There are several potential limitations to this study. This
was a 15-month cross sectional study and we cannot rule
out the chance that the outcome (poor LDL or BP control)
affected processes of care due to measurement overlap.
However, our main objective was to identify an associa-
tion between these factors and not to establish temporal
associations between the independent and dependent var-
iables. Second, we arbitrarily defined a timeframe to
assess for the presence of outcomes. Patients could have
had a measurement just prior to or after the defined time
periods. The defined time periods however, were longer
than guideline recommendations for follow-up of LDL
cholesterol and BP [6,14] even among patients who have
achieved target goals. Third, although the database
included complete laboratory, pharmacy records, and
visit histories from all Pacific Northwest VA facilities,
information from outside the VA system was not availa-
ble. Nevertheless, patients in the study had an average of
9 clinic visits during the study period and were prescribed
an average of 11 medications and it was likely that we cap-
tured a significant proportion of all health care utilization
by these patients. Lastly, the guideline targets used for the
study were applicable to both patients with and without
known IHD. The BP targets were SBP<140 and DBP<90
mm Hg [14], which are the same for patients without
known IHD. Therefore, the blood pressure goals estab-
lished for this study should be achieved in all patients
regardless of ischemic heart disease status.
Conclusion
We found that less than one-quarter of patients with
known ischemic heart disease have achieved both LDL
cholesterol and BP targets as recommended by national
guidelines. Patients at the highest risk for guideline non-
concordance can be identified based on four factors,
including age≥65, presence of vascular disease, lack of dia-
betes and lack of recent cardiac hospitalization. Quality
improvement efforts are urgently needed to improve
upon these secondary prevention measures to reduce the
morbidity and mortality of patients with known ischemic
heart disease.
List of abbreviations
ACS: Acute Coronary Syndrome
BP: Blood pressure
CABG: Coronary Artery Bypass Graft
DBP: Diastolic blood pressure
IHD: Ischemic heart disease
ICD-9: International Classification of Diseases-9th revi-
sion diagnosis
LDL: Low density lipoprotein
OPC: Outpatient Care File
PTF: Patient Treatment File
PCI: Percutaneous Coronary Intervention
SBP: Systolic blood pressure
VA: Department of Veteran Affairs
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All authors contributed to the conception, design, and
interpretation of the data. PMH performed the statistical
analysis and drafted the article. All authors were involved
in the revision. All authors gave final approval of the ver-
sion to be published.
Acknowledgements
The views expressed in this article are those of the authors and do not nec-
essarily represent the views of the Department of Veterans Affairs. Dr. 
Rumsfeld was supported by a VA Health Services Advanced Research 
Career Development Award (RCD 98341-2).
References
1. Johnson ML, Pietz K, Battleman DS, Beyth RJ: Prevalence of
comorbid hypertension and dyslipidemia and associated car-
diovascular disease.  Am J Manag Care 2004, 10(12):926-32.
2. Sloan KL, Sales AE, Willems JP, Every NR, Martin GV, Sun H, Pineros
S, Sharp N: Frequency of serum low-density lipoprotein cho-
lesterol measurement and frequency of results < or = 100
mg/dl among patients who had coronary events (Northwest
VA Network Study).  Am J Cardiol 2001, 88:1143-6.
3. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM,
Londhe A, Lulla A, Simpson RJ Jr: Analysis of the degree of under-
treatment of hyperlipidemia and congestive heart failure
secondary to coronary artery disease.  Am J Cardiol 1999,
83:1303-7.
4. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader
B, Moskowitz MA: Inadequate management of blood pressure
in a hypertensive population.  N Engl J Med 339(27):1957-63.
1998 Dec 31
5. Hyman DJ, Pavlik VN: Characteristics of patients with uncon-
trolled hypertension in the United States.  N Engl J Med
345(7):479-86. 2001 Aug 16
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults: Executive summary of the third report
of the National Cholesterol Education Program (NCEP)Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cardiovascular Disorders 2006, 6:6 http://www.biomedcentral.com/1471-2261/6/6
Page 8 of 8
(page number not for citation purposes)
expert panel on detection, evaluation, and treatment of high
blood cholesterol in adults (Adult Treatment Panel III).  JAMA
2001, 285:2486-97.
7. American Heart Association: Heart Disease and Stroke Statistics-2005
Update Dallas, Tex.: American Heart Association; 2005. 
8. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H,
Kannel WB: Prediction of coronary heart disease using risk
factor categories.  Circulation 1998, 97:1837-47.
9. Donabedian A: The quality of care.  JAMA 1988, 260:1742-48.
10. Ho PM, Masoudi FA, Peterson ED, Grunwald GK, Sales AE, Hammer-
meister KE, Rumsfeld JS: Cardiology involvement improves sec-
ondary prevention measures among patients with coronary
artery disease.  J Am Coll Cardiol 2004, 43:1517-23.
11. Consumer Health Information & Performance Sets (CHIPS)
website   [http://vaww.visn20.med.va.gov/technology/datman/
index.html]. Accessed March 21, 2005
12. Meridian World Data   [http://www.meridianworlddata.com]
13. VISN 20 website   [http://vaww.visn20.med.va.gov/index.html].
Accessed March 21, 2005
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo
JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ,
National Heart, Lung, and Blood Institute Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of High Blood
Pressure; National High Blood Pressure Education Program Coordi-
nating Committee: The Seventh Report of the Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure: The JNC 7 report.  JAMA
289(19):2560-72. Epub 2003 May 14, 2003 May 21
15. SAS Institute Inc: SAS/STAT software, Release 8.02 Cary, NC: SAS Insti-
tute Inc; 2002. 
16. Davidson MH, Maki KC, Pearson TA, et al.:  Undertreatment
among high-risk dyslipidemic patients: Results of a national
survey of goal achievement for national cholesterol educa-
tion program adult treatment panel III guidelines.  Drugs
Affecting Lipid Metabolism meeting; October 24–27; Venice, Italy .
Abstract 204
17. Lloyd-Jones DM, Evans JC, Larson MG, Levy D: Treatment and
control of hypertension in the community: A prospective
analysis.  Hypertension 2002, 40(5):640-6.
18. Pedrinelli R, Degli Esposti E, Dell'Omo G: LDL cholesterol and
global risk stratification in referred hypertensive patients.
Atherosclerosis 2005, 180:137-143.
19. Jha AK, Perlin JB, Kizer KW, Dudley RA: Effect of the transforma-
tion of the Veterans Affairs Health Care System and the
quality of care.  New Engl J Med 2003, 348:2218-27.
20. Asch SM, McGlynn EA, Hogan MM, Hayward RA, Shekelle P, Ruben-
stein L, Keesey J, Adams J, Kerr EA: Comparison of quality of care
for patients in the Veterans Health Administration and
patients in a national sample.  Ann Intern Med 2004, 141:938-45.
21. Khoury AT, Wan GJ, Niedermaier ON, LeBrun B, Stiebeling B, Roth
M, Alexander CM: Improved cholesterol management in coro-
nary heart disease patients enrolled in an HMO.  J Healthc Qual
2001, 23(2):29-33.
22. Tu K, Davis D: Can we alter physician behavior by educational
methods? Lessons learned from studies of the management
and follow-up of hypertension.  J Contin Educ Health Prof 2002,
Winter;22(1):11-22.
23. Wagner EH, Davis C, Schaefer J, Von Korff M, Austin B: A survey of
leading chronic disease management programs: are they
consistent with the literature.  Managed Care Quarterly 1999,
7:56-66.
24. Ara S: A literature review of cardiovascular disease manage-
ment programs in managed care populations.  J Manag Care
Pharm 2004, 10:326-44.
25. Piette JD: Interactive voice response systems in the diagnosis
and management of chronic disease.  Am J Manag Car 2000,
6:817-27.
26. Huddleston M, Kobb R: Emerging technology for at-risk chron-
ically ill veterans.  J Healthc Qual 2004, 26(6):12-5. 24
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2261/6/6/prepub